Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Read
S&P 500 Tops $2600: ETFs & Stocks That Deserve Special Thanks
Article By:
Sweta Killa
Wednesday, November 22, 2017 1:21 PM EDT
Holiday optimism is pushing the stocks higher. While there have been winners in every corner of the space, a few ETFs & stocks have easily crushed the broad market in the year-to-date period.
Best Performing Stocks YTD Through Q3 2017
Article By:
Bespoke Investment Group
Monday, October 2, 2017 12:30 PM EDT
I have created a list of 40 best performing Russell 3,000 stocks on a year-to-date basis through the third quarter of 2017. A bulk of the names on the list of biggest winners are from the Biotech space.
In this article: WTW, STRP, SGMO, TREE, CUTR, FIZZ, SGMS, UCTT, DVAX, CTRL, SQ, PIRS, EVRI, CALA, CAI
MyoKardia Brings Hope To Hypertrophic Cardiomyopathy Patients
Article By:
Scott Matusow
Tuesday, July 11, 2017 10:44 AM EDT
Obstructive Hypertrophic Cardiomyopathy affects roughly 1 out of 500 persons in the U.S, and globally. MyoKardia based on my research has a good chance to successfully treat this highly underserved and unmet need patient population.
GlycoMimetics - High Potential Clinical-Stage Biotech
Article By:
Scott Matusow
Tuesday, May 16, 2017 9:01 AM EDT
GlycoMimetics is a clinical-stage biotech that we feel has significant potential to be a short, mid, and long term winner. The company has a unique and novel platform in which early data looks very promising.
Calithera Biosciences: An Under The Radar Opportunity
$CALA sounds like a good buy.